Compare SKM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKM | PRAX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.2B |
| IPO Year | 1996 | 2020 |
| Metric | SKM | PRAX |
|---|---|---|
| Price | $20.60 | $289.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | N/A | ★ $373.79 |
| AVG Volume (30 Days) | ★ 670.1K | 615.7K |
| Earning Date | 02-11-2026 | 02-27-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $12,327,044,068.00 | $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.05 | $12,467.71 |
| P/E Ratio | $19.37 | ★ N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $19.66 | $26.70 |
| 52 Week High | $23.80 | $317.72 |
| Indicator | SKM | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 62.90 |
| Support Level | $20.32 | $268.78 |
| Resistance Level | $20.75 | $317.72 |
| Average True Range (ATR) | 0.19 | 13.98 |
| MACD | 0.07 | -3.34 |
| Stochastic Oscillator | 83.49 | 50.81 |
SK Telecom is South Korea's largest wireless telecom operator, with 32 million mobile customers. The firm also owns SK Broadband (formerly Hanaro Telecom), which has 7.2 million broadband customers and 9.5 million pay TV customers (6.7 million IPTV and 2.8 million Cable TV). While the firm also purchased stakes in businesses in security and semiconductor memory production as well as developing e-commerce and internet platform businesses, these were all spun off into the separate, SK Square business in November 2021. The company was formed after SK Group purchased KT's mobile business in 1994.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.